Oxatomide
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Oxatomide is an antihistamine indicated in the treatment and prevention of allergic symptoms.
- Generic Name
- Oxatomide
- DrugBank Accession Number
- DB12877
- Background
Oxatomide has been used in trials studying the treatment of Muscular Dystrophy, Duchenne.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
- Weight
- Average: 426.564
Monoisotopic: 426.241961602 - Chemical Formula
- C27H30N4O
- Synonyms
- Oxatomida
- Oxatomide
- Oxatomidum
- External IDs
- KW-4354
- McN-JR 35443
- R 35 443
- R 35,443
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Asthma, allergic •••••••••••• Treatment of Atopic dermatitis (ad) •••••••••••• Treatment of Chronic urticaria •••••••••••• Symptomatic treatment of Pruritus •••••••••••• ••• Treatment of Rhinitis •••••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AHistamine H1 receptor antagonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
Pathway Category Oxatomide H1-Antihistamine Action Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Oxatomide. Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Oxatomide. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Oxatomide. Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Oxatomide. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Oxatomide. - Food Interactions
- Take with food.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Celtect / Tinset
Categories
- ATC Codes
- R06AE06 — Oxatomide
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylmethanes
- Direct Parent
- Diphenylmethanes
- Alternative Parents
- Benzimidazoles / N-alkylpiperazines / Aralkylamines / N-substituted imidazoles / Heteroaromatic compounds / Ureas / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds show 2 more
- Substituents
- 1,4-diazinane / Amine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzimidazole / Diphenylmethane / Heteroaromatic compound / Hydrocarbon derivative show 14 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- J31IL9Z2EE
- CAS number
- 60607-34-3
- InChI Key
- BAINIUMDFURPJM-UHFFFAOYSA-N
- InChI
- InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
- IUPAC Name
- 1-{3-[4-(diphenylmethyl)piperazin-1-yl]propyl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
- SMILES
- O=C1NC2=C(C=CC=C2)N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
References
- General References
- AIFA Product Information: Tinset (oxatomide) for oral and topical use [Link]
- External Links
- Human Metabolome Database
- HMDB0240225
- KEGG Drug
- D01773
- PubChem Compound
- 4615
- PubChem Substance
- 347829033
- ChemSpider
- 4454
- BindingDB
- 76863
- 54236
- ChEBI
- 31943
- ChEMBL
- CHEMBL13828
- ZINC
- ZINC000019632896
- PharmGKB
- PA163522137
- Wikipedia
- Oxatomide
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Duchenne Muscular Dystrophy (DMD) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Gel Topical 5 % Solution / drops Oral 0.25 % Solution / drops Oral 25 MG/ML Suspension Oral 25 mg/ml Tablet Oral 30 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0393 mg/mL ALOGPS logP 4.71 ALOGPS logP 4.62 Chemaxon logS -4 ALOGPS pKa (Strongest Acidic) 12.92 Chemaxon pKa (Strongest Basic) 8.01 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 38.82 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 130.94 m3·mol-1 Chemaxon Polarizability 48.79 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-004i-0000900000-84097f466ddfe2917175 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0a6r-1002900000-96951933e0b5d1584ca2 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0a59-0009800000-980f59ed3c95834dd143 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-003r-0409700000-b39266881c3ac80d372f Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-05qc-4419100000-437c10106d065b610e50 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-001m-4926100000-b7d424c751f8d20a8d7c Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 226.8030499 predictedDarkChem Lite v0.1.0 [M-H]- 226.4143499 predictedDarkChem Lite v0.1.0 [M-H]- 194.38414 predictedDeepCCS 1.0 (2019) [M+H]+ 226.0054499 predictedDarkChem Lite v0.1.0 [M+H]+ 226.4351499 predictedDarkChem Lite v0.1.0 [M+H]+ 196.74214 predictedDeepCCS 1.0 (2019) [M+Na]+ 226.3233499 predictedDarkChem Lite v0.1.0 [M+Na]+ 225.8700499 predictedDarkChem Lite v0.1.0 [M+Na]+ 203.57559 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsHistamine H1 receptor
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- G-protein-coupled receptor for histamine, a biogenic amine that functions as an immune modulator and a neurotransmitter (PubMed:33828102, PubMed:8280179). Through the H1 receptor, histamine mediates the contraction of smooth muscles and increases capillary permeability due to contraction of terminal venules. Also mediates neurotransmission in the central nervous system and thereby regulates circadian rhythms, emotional and locomotor activities as well as cognitive functions (By similarity)
- Specific Function
- G protein-coupled serotonin receptor activity
- Gene Name
- HRH1
- Uniprot ID
- P35367
- Uniprot Name
- Histamine H1 receptor
- Molecular Weight
- 55783.61 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Drug created at October 21, 2016 00:57 / Updated at August 26, 2024 19:24